Open-label, dose escalation study of the safety and pharmacokinetic profile of tefibazumab in healthy volunteers.
about
Safety and pharmacokinetics of urtoxazumab, a humanized monoclonal antibody, against Shiga-like toxin 2 in healthy adults and in pediatric patients infected with Shiga-like toxin-producing Escherichia coliMulticenter study to determine antibody concentrations and assess the safety of administration of INH-A21, a donor-selected human Staphylococcal immune globulin, in low-birth-weight infants.Characterization of the opsonic and protective activity against Staphylococcus aureus of fully human monoclonal antibodies specific for the bacterial surface polysaccharide poly-N-acetylglucosamine.Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremiaPhase I dose escalation study to evaluate the safety and pharmacokinetic profile of tefibazumab in subjects with end-stage renal disease requiring hemodialysisFirst human study of a chimeric anti-methamphetamine monoclonal antibody in healthy volunteersEmerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections.Antibodies to capsular polysaccharide and clumping factor A prevent mastitis and the emergence of unencapsulated and small-colony variants of Staphylococcus aureus in mice.Giving monoclonal antibodies to healthy volunteers in phase 1 trials: is it safe?Open-label, dose escalation phase I study in healthy volunteers to evaluate the safety and pharmacokinetics of a human monoclonal antibody to Clostridium difficile toxin A.Determination of the starting dose in the first-in-human clinical trials with monoclonal antibodies: a systematic review of papers published between 1990 and 2013Invasive community-associated MRSA infections: epidemiology and antimicrobial management.Novel targets for antibiotics in Staphylococcus aureus.A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-Sim.
P2860
Q24653814-51C3759D-9C0F-4D86-966B-7718DEF56D41Q34077073-E02881EF-21AE-447A-8FB4-483737E159A2Q34601937-EB3F8FAE-3B73-43F5-859B-4715B23137F8Q34973729-B607A82A-E3FF-4169-833D-9599F757B378Q35091505-27AD4F69-48EF-416F-88A2-89EB42E557CEQ36215915-CCC38CB6-7E2D-4BB4-BD85-88604732EFD3Q36718474-60F35049-812F-448A-B898-FC0A5E8C4454Q36974423-22BE6E58-8CA2-4823-9910-58086F2831ABQ37064733-4F86C219-AAA1-4AE9-B186-4928A5D03A04Q37067252-BC669826-C2A8-4FA0-A440-7A78E750267AQ37496388-91C8A75E-6099-4F7D-ADC9-577724893EEAQ37800939-4E306437-0D81-4610-8EBA-856439517C14Q40149893-CFF80D2C-1432-426E-9768-8E05DE4C33AEQ46242399-BE2F45F3-B7E0-4319-B4DC-6B77FC3C2D54
P2860
Open-label, dose escalation study of the safety and pharmacokinetic profile of tefibazumab in healthy volunteers.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մարտին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Open-label, dose escalation st ...... bazumab in healthy volunteers.
@ast
Open-label, dose escalation st ...... bazumab in healthy volunteers.
@en
type
label
Open-label, dose escalation st ...... bazumab in healthy volunteers.
@ast
Open-label, dose escalation st ...... bazumab in healthy volunteers.
@en
prefLabel
Open-label, dose escalation st ...... bazumab in healthy volunteers.
@ast
Open-label, dose escalation st ...... bazumab in healthy volunteers.
@en
P2093
P2860
P1476
Open-label, dose escalation st ...... bazumab in healthy volunteers.
@en
P2093
Beth Bennett
Eric Wenzel
Joseph M Patti
Laurie Reynolds
Sandra Reilley
Seth Hetherington
P2860
P304
P356
10.1128/AAC.49.3.959-962.2005
P407
P50
P577
2005-03-01T00:00:00Z